/PRNewswire/ The "Cell & Gene Therapy Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com s offering. The cell and.
Share:
MILAN, Italy and NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced it will be presenting at several upcoming scientific congresses in May and June.
Details of the presentations are as follows:
American Society of Cell and Gene Therapy (ASGCT) 24
th Annual Meeting, May 11-14, virtual
Title: Changes in the Tumor Microenvironment in Patients with Glioblastoma Multiforme Treated with IFN-a Immune Cell & Gene Therapy (TEM-GBM 001 Study)
Type: Oral presentation
2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, virtual
Title: A phase I-IIa study of genetically modified Tie-2 expressing monocytes in patients with glioblastoma multiforme (TEM-GBM Study)
Operator
Good afternoon, and welcome to the REGENXBIO First Quarter 2021 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the call over to Mr. Patrick Christmas, Chief Legal Officer of REGENXBIO. You may begin.
Patrick J. Christmas II, J.D.
Chief Legal Officer
Good afternoon, and thank you for joining us. With us today are Ken Mills, REGENXBIO s President and Chief Executive Officer; and Dr. Steve Pakola, our Chief Medical Officer. Earlier this afternoon, REGENXBIO released financial and operating results for the first quarter ended March 31, 2021. The press release reporting our financial results is available on our website at www.regenxbio.com. Today s conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results